Farallon Capital Management’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Farallon Capital Management’s Portfolio ISEE Stock Details ISEE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,442,299	Closed	-$96.1M	–	198
2023 Q2	$96.1M	Buy	2,442,299 +1,957,500	+404%	+$69.1M	0.48%	49
2023 Q1	$11.8M	Sell	484,799 -977,201	-67%	-$21.4M	0.06%	94
2022 Q4	$31.3M	Buy	1,462,000 +145,000	+11%	+$3.09M	0.18%	72
2022 Q3	$23.6M	Buy	+1,317,000	New	+$17.3M	0.13%	95
2021 Q1	–	Sell	-754,740	Closed	-$5.21M	–	251
2020 Q4	$5.21M	Hold	754,740	–	–	0.03%	121
2020 Q3	$4.26M	Buy	754,740 +4,740	+0.6%	+$22.6K	0.03%	111
2020 Q2	$3.83M	Buy	+750,000	New	+$3.12M	0.03%	112

Farallon Capital Management's ISEE Position: Q3 2023 in Review

Farallon Capital Management sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 2,442,299 shares — an estimated $96.1M sold.

Farallon Capital Management first reported a position in ISEE in Q2 2020 and held it in 7 quarters. The position peaked at $96.1M in Q2 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.

Farallon Capital Management reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Farallon Capital Management sold 2,442,299 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $96.1M.
Farallon Capital Management first reported a position in IVERIC bio, Inc. Common Stock in Q2 2020 and held it in 7 quarters.
Farallon Capital Management's IVERIC bio, Inc. Common Stock position peaked at $96.1M in Q2 2023.
0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.

Based on Farallon Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.